In vitro study demonstrates that miR-377 suppresses tumor progression by targeting MYC in prostate cancer cells, suggesting its potential value as a therapeutic target.
Background: The MYC gene is one of the regulatory and proto-oncogenic genes overexpressed in most prostate cancers (PCa). Studies have shown that abnormal expression of microRNAs is involved in the onset and development of many different types of human cancer, including prostate cancer. Methods and result: In this study, we first evaluated targeting the effect of miR-377 on MYC by luciferase assay. Real-time PCR was used to determine whether miR-377 could decrease the MYC mRNA in transfected PCa cell lines (PC-3 and DU145). Also, the expression of BCL-2/Bax, PTEN, and CDK4 mRNA levels were measured due to MYC degression. Also, the effects of miR-377 on apoptosis cells, proliferation, cell cycle, and wound healing were analyzed. We showed that miR-377 targets MYC mRNA by luciferase reporter assay. A significant reduction in MYC mRNA level was detected following miR-377 transfection in PC-3 and DU145 cell lines. Also, we demonstrated the decrease of BCL-2 and CDK4 and an increase in Bax, and PTEN in prostate cancer cell lines, following the reduction of MYC. Furthermore, we showed that the higher levels of miR-377 in PCa cell lines induced apoptosis, reduced proliferation, and migration, and stopped the cell cycle. Conclusion: All these data reveal that miR-377 functions as an MYC inhibitor in PCa and may serve as a potential therapeutic target for treating this cancer.
No takes yet. Share an insight, caveat, or question.
Azimi et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: